Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Jan 5;11:780655. doi: 10.3389/fonc.2021.780655

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2022 Shen, Qi, Ren, Lv and Yang

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Outcomes vary in primary treatments in different KRAS mutation subtypes or different KRAS co-mutations. (A) Pooled PFS of NSCLC patients with KRAS wild-type and different KRAS mutations from clinical trials. (B) Pooled PFS of K-only and KRAS co-mutated patients with NSCLC from clinical trials. KRAS, kirten rat sarcoma viral oncogene homolog; COD, codon; WT, wild type; ICIs, immune checkpoint inhibitors; BEV, bevacizumab; CHT, chemotherapy; KS, KRAS-SAMARCA4 co-mutant; KL, KRAS-STK11/LKB1 co-mutant; KP, KRAS-KEAP1 co-mutant; PFS, progression-free survival; NSCLC, non-small cell lung cancer.